The Post had an article this morning reporting on an experimental cancer treatment in China which a pharmaceutical company in the United States claims is "stolen." While there is an important issue about safety standards (China is almost certainly far more lax than the United States), this is an interesting example of how patents can impede the development of new drugs.
Assuming the the U.S. firm is correct in its claim that the Chinese company is infringing on its patents (this is disputed), then effective patent enforcement would have prevented the Chinese firm from advancing research on this form of treatment. Science advances most quickly when results are fully public and all researchers are allowed to carry through research that they deem important. In a world where the quest for patent monopolies closes off large areas to researchers, medicine will almost certainly advance less quickly than in a world in which all research is fully public.
If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.
Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.
Join our community of supporters and make a donation today to help keep independent journalism thriving.
Copyright 2024 | The American Prospect, Inc. | All Rights Reserved
